Glucocorticoid-Associated Demise of a Patient with Duchenne Muscular Dystrophy

Alexander E. Brahmsteadt; John R. Bach; Reza Pishdad; Lissette Cespedes; Paola Pierucci

doi:10.1097/PHM.0000000000001426

Glucocorticoid-Associated Demise of a Patient with Duchenne Muscular Dystrophy

Alexander E. Brahmsteadt, John R. Bach, Reza Pishdad, Lissette Cespedes, Paola Pierucci

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

We describe the clinical deterioration of a 26-yr-old man with Duchenne muscular dystrophy on oral daily high-dose deflazacort. Although this daily regimen was targeted to benefit ambulation and respiration, it resulted in premature death with lethal sequelae from liver failure, decubiti, diabetes mellitus, and morbid obesity. This case illustrates the need for further research weighing risk versus benefit of daily glucocorticoid therapy, specifically deflazacort, in Duchenne muscular dystrophy patients. Thus, curtailment of daily dosing to eliminate dire sequelae in patients living longer into adulthood than ever before is recommended.

Original language	English (US)
Pages (from-to)	e146-e148
Journal	American Journal of Physical Medicine and Rehabilitation
Volume	99
Issue number	12
DOIs	https://doi.org/10.1097/PHM.0000000000001426
State	Published - Dec 2020

All Science Journal Classification (ASJC) codes

Physical Therapy, Sports Therapy and Rehabilitation
Rehabilitation

Keywords

Deflazacort
Duchenne Muscular Dystrophy
Glucocorticoid
Neuromuscular Disease

Access to Document

10.1097/PHM.0000000000001426

Cite this

@article{df828bf8640f44218e052a53ada642d3,

title = "Glucocorticoid-Associated Demise of a Patient with Duchenne Muscular Dystrophy",

abstract = "We describe the clinical deterioration of a 26-yr-old man with Duchenne muscular dystrophy on oral daily high-dose deflazacort. Although this daily regimen was targeted to benefit ambulation and respiration, it resulted in premature death with lethal sequelae from liver failure, decubiti, diabetes mellitus, and morbid obesity. This case illustrates the need for further research weighing risk versus benefit of daily glucocorticoid therapy, specifically deflazacort, in Duchenne muscular dystrophy patients. Thus, curtailment of daily dosing to eliminate dire sequelae in patients living longer into adulthood than ever before is recommended.",

keywords = "Deflazacort, Duchenne Muscular Dystrophy, Glucocorticoid, Neuromuscular Disease",

author = "Brahmsteadt, {Alexander E.} and Bach, {John R.} and Reza Pishdad and Lissette Cespedes and Paola Pierucci",

year = "2020",

month = dec,

doi = "10.1097/PHM.0000000000001426",

language = "English (US)",

volume = "99",

pages = "e146--e148",

journal = "American Journal of Physical Medicine and Rehabilitation",

issn = "0894-9115",

publisher = "Lippincott Williams and Wilkins",

number = "12",

}

TY - JOUR

T1 - Glucocorticoid-Associated Demise of a Patient with Duchenne Muscular Dystrophy

AU - Brahmsteadt, Alexander E.

AU - Bach, John R.

AU - Pishdad, Reza

AU - Cespedes, Lissette

AU - Pierucci, Paola

PY - 2020/12

Y1 - 2020/12

N2 - We describe the clinical deterioration of a 26-yr-old man with Duchenne muscular dystrophy on oral daily high-dose deflazacort. Although this daily regimen was targeted to benefit ambulation and respiration, it resulted in premature death with lethal sequelae from liver failure, decubiti, diabetes mellitus, and morbid obesity. This case illustrates the need for further research weighing risk versus benefit of daily glucocorticoid therapy, specifically deflazacort, in Duchenne muscular dystrophy patients. Thus, curtailment of daily dosing to eliminate dire sequelae in patients living longer into adulthood than ever before is recommended.

AB - We describe the clinical deterioration of a 26-yr-old man with Duchenne muscular dystrophy on oral daily high-dose deflazacort. Although this daily regimen was targeted to benefit ambulation and respiration, it resulted in premature death with lethal sequelae from liver failure, decubiti, diabetes mellitus, and morbid obesity. This case illustrates the need for further research weighing risk versus benefit of daily glucocorticoid therapy, specifically deflazacort, in Duchenne muscular dystrophy patients. Thus, curtailment of daily dosing to eliminate dire sequelae in patients living longer into adulthood than ever before is recommended.

KW - Deflazacort

KW - Duchenne Muscular Dystrophy

KW - Glucocorticoid

KW - Neuromuscular Disease

UR - http://www.scopus.com/inward/record.url?scp=85096508903&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85096508903&partnerID=8YFLogxK

U2 - 10.1097/PHM.0000000000001426

DO - 10.1097/PHM.0000000000001426

M3 - Article

C2 - 32195738

AN - SCOPUS:85096508903

SN - 0894-9115

VL - 99

SP - e146-e148

JO - American Journal of Physical Medicine and Rehabilitation

JF - American Journal of Physical Medicine and Rehabilitation

IS - 12

ER -

Glucocorticoid-Associated Demise of a Patient with Duchenne Muscular Dystrophy

Abstract

All Science Journal Classification (ASJC) codes

Keywords

Access to Document

Other files and links

Fingerprint

Cite this